Orlaam / Levomethadyl

Modified on 2009/10/14 21:34 by admin
Orlaam, also known as Levomethadyl, is marketed by the Boehringer Ingelheim Company and was approved by the Food and Drug Administration in the early 1990s as a treatment for addiction to opiates and narcotics. The drug has been used in the treatment of heroin and other addictions. While Orlaam does not cure addiction, it lessens the severity of withdrawal symptoms that often occur when an addict no longer has access to the addictive substance. Occasionally Orlaam is used with other withdrawal drugs such as methadone.

Recently, reports have surfaced that Orlaam may be responsible for heart rhythm disorders that have killed at least 10 otherwise healthy young adults.

In September 2003, Roxane Laboratories, Inc. discontinued the sale and distribution of Orlaam. Orlaam was removed from the European market in March 2001 following reports of severe cardiac-related adverse events, including QT interval prolongation, Torsades de Pointes and cardiac arrest. Other first-line treatment options are available for the management of opiate dependence, including methadone and buprenorphine. Roxane estimates that the current inventory of this product will be depleted by February 2004 and encouraged healthcare providers to transfer patients to alternative treatments as soon as possible prior to the product's unavailability.

See your doctor if you have developed a heart rhythm or other physical disorder after taking Orlaam. In addition, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Addiction Treatment: Overview
  2. Arrhythmia: Overview
  3. Heart Attack Lawsuits
  4. QT Interval: Overview
  5. Torsades de Pointes: Overview
  6. Orlaam: Frequently Asked Questions
  Name Size